Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma

Neal W. Wilkinson, Jennifer D. Black, Elena Roukhadze, Deborah Driscoll, Shannon Smiley, Hisakazu Hoshi, Joseph Geradts, Milind Javle, Michael Brattain

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Activation of the epidermal growth factor receptor (EGFR) has a role in oncogenesis and may correlate with prognosis. The aim of this study was to examine EGFR expression in esophageal adenocarcinoma and correlate EGFR status with pathologic and clinical prognostic features. An exploratory retrospective review of 38 patients with surgically resected esophageal adenocarcinoma was performed. All patients underwent an esophagogastrectomy with regional lymphadenectomy; 24 patients underwent primary resection and 14 patients had surgery after preoperative chemoradiation therapy. Immunohistochemical analysis was performed on paraffin-embedded tissue samples using an EGFR monoclonal antibody. Low- and moderate-grade tumors were positive for EGFR expression in 2 of 15 patients; poorly differentiated tumors were positive for EGFR expression in 13 of 23 patients (p=0.02). The median survival was 35 months (confidence interval [CI]: 29-40) for EGFR negative patients (n=23) and 16 months (CI: 10-22) for EGFR positive patients (n=13) (p=0.10). Disease recurred in 3 of 21 EGFR negative patients and 6 of 13 EGFR positive patients (p=0.06). Poorly differentiated adenocarcinomas of the esophagus demonstrated higher EGFR expression compared to low-grade tumors based upon immunohistochemical analysis. A trend toward improved disease-free and overall survival was seen in EGFR negative patients.

Original languageEnglish (US)
Pages (from-to)448-453
Number of pages6
JournalJournal of Gastrointestinal Surgery
Volume8
Issue number4
DOIs
StatePublished - May 1 2004

Fingerprint

Epidermal Growth Factor Receptor
Adenocarcinoma
Confidence Intervals
Neoplasms
Lymph Node Excision
Paraffin
Disease-Free Survival
Carcinogenesis
Monoclonal Antibodies
Survival

Keywords

  • Esophageal adenocarcinoma
  • epidermal growth factor receptor
  • immunohistochemical analysis
  • tyrosine kinase receptors

ASJC Scopus subject areas

  • Surgery
  • Gastroenterology

Cite this

Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma. / Wilkinson, Neal W.; Black, Jennifer D.; Roukhadze, Elena; Driscoll, Deborah; Smiley, Shannon; Hoshi, Hisakazu; Geradts, Joseph; Javle, Milind; Brattain, Michael.

In: Journal of Gastrointestinal Surgery, Vol. 8, No. 4, 01.05.2004, p. 448-453.

Research output: Contribution to journalArticle

Wilkinson, NW, Black, JD, Roukhadze, E, Driscoll, D, Smiley, S, Hoshi, H, Geradts, J, Javle, M & Brattain, M 2004, 'Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma', Journal of Gastrointestinal Surgery, vol. 8, no. 4, pp. 448-453. https://doi.org/10.1016/j.gassur.2004.01.006
Wilkinson, Neal W. ; Black, Jennifer D. ; Roukhadze, Elena ; Driscoll, Deborah ; Smiley, Shannon ; Hoshi, Hisakazu ; Geradts, Joseph ; Javle, Milind ; Brattain, Michael. / Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma. In: Journal of Gastrointestinal Surgery. 2004 ; Vol. 8, No. 4. pp. 448-453.
@article{b00e467b140b4301bb4f8e0b06978dc2,
title = "Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma",
abstract = "Activation of the epidermal growth factor receptor (EGFR) has a role in oncogenesis and may correlate with prognosis. The aim of this study was to examine EGFR expression in esophageal adenocarcinoma and correlate EGFR status with pathologic and clinical prognostic features. An exploratory retrospective review of 38 patients with surgically resected esophageal adenocarcinoma was performed. All patients underwent an esophagogastrectomy with regional lymphadenectomy; 24 patients underwent primary resection and 14 patients had surgery after preoperative chemoradiation therapy. Immunohistochemical analysis was performed on paraffin-embedded tissue samples using an EGFR monoclonal antibody. Low- and moderate-grade tumors were positive for EGFR expression in 2 of 15 patients; poorly differentiated tumors were positive for EGFR expression in 13 of 23 patients (p=0.02). The median survival was 35 months (confidence interval [CI]: 29-40) for EGFR negative patients (n=23) and 16 months (CI: 10-22) for EGFR positive patients (n=13) (p=0.10). Disease recurred in 3 of 21 EGFR negative patients and 6 of 13 EGFR positive patients (p=0.06). Poorly differentiated adenocarcinomas of the esophagus demonstrated higher EGFR expression compared to low-grade tumors based upon immunohistochemical analysis. A trend toward improved disease-free and overall survival was seen in EGFR negative patients.",
keywords = "Esophageal adenocarcinoma, epidermal growth factor receptor, immunohistochemical analysis, tyrosine kinase receptors",
author = "Wilkinson, {Neal W.} and Black, {Jennifer D.} and Elena Roukhadze and Deborah Driscoll and Shannon Smiley and Hisakazu Hoshi and Joseph Geradts and Milind Javle and Michael Brattain",
year = "2004",
month = "5",
day = "1",
doi = "10.1016/j.gassur.2004.01.006",
language = "English (US)",
volume = "8",
pages = "448--453",
journal = "Journal of Gastrointestinal Surgery",
issn = "1091-255X",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma

AU - Wilkinson, Neal W.

AU - Black, Jennifer D.

AU - Roukhadze, Elena

AU - Driscoll, Deborah

AU - Smiley, Shannon

AU - Hoshi, Hisakazu

AU - Geradts, Joseph

AU - Javle, Milind

AU - Brattain, Michael

PY - 2004/5/1

Y1 - 2004/5/1

N2 - Activation of the epidermal growth factor receptor (EGFR) has a role in oncogenesis and may correlate with prognosis. The aim of this study was to examine EGFR expression in esophageal adenocarcinoma and correlate EGFR status with pathologic and clinical prognostic features. An exploratory retrospective review of 38 patients with surgically resected esophageal adenocarcinoma was performed. All patients underwent an esophagogastrectomy with regional lymphadenectomy; 24 patients underwent primary resection and 14 patients had surgery after preoperative chemoradiation therapy. Immunohistochemical analysis was performed on paraffin-embedded tissue samples using an EGFR monoclonal antibody. Low- and moderate-grade tumors were positive for EGFR expression in 2 of 15 patients; poorly differentiated tumors were positive for EGFR expression in 13 of 23 patients (p=0.02). The median survival was 35 months (confidence interval [CI]: 29-40) for EGFR negative patients (n=23) and 16 months (CI: 10-22) for EGFR positive patients (n=13) (p=0.10). Disease recurred in 3 of 21 EGFR negative patients and 6 of 13 EGFR positive patients (p=0.06). Poorly differentiated adenocarcinomas of the esophagus demonstrated higher EGFR expression compared to low-grade tumors based upon immunohistochemical analysis. A trend toward improved disease-free and overall survival was seen in EGFR negative patients.

AB - Activation of the epidermal growth factor receptor (EGFR) has a role in oncogenesis and may correlate with prognosis. The aim of this study was to examine EGFR expression in esophageal adenocarcinoma and correlate EGFR status with pathologic and clinical prognostic features. An exploratory retrospective review of 38 patients with surgically resected esophageal adenocarcinoma was performed. All patients underwent an esophagogastrectomy with regional lymphadenectomy; 24 patients underwent primary resection and 14 patients had surgery after preoperative chemoradiation therapy. Immunohistochemical analysis was performed on paraffin-embedded tissue samples using an EGFR monoclonal antibody. Low- and moderate-grade tumors were positive for EGFR expression in 2 of 15 patients; poorly differentiated tumors were positive for EGFR expression in 13 of 23 patients (p=0.02). The median survival was 35 months (confidence interval [CI]: 29-40) for EGFR negative patients (n=23) and 16 months (CI: 10-22) for EGFR positive patients (n=13) (p=0.10). Disease recurred in 3 of 21 EGFR negative patients and 6 of 13 EGFR positive patients (p=0.06). Poorly differentiated adenocarcinomas of the esophagus demonstrated higher EGFR expression compared to low-grade tumors based upon immunohistochemical analysis. A trend toward improved disease-free and overall survival was seen in EGFR negative patients.

KW - Esophageal adenocarcinoma

KW - epidermal growth factor receptor

KW - immunohistochemical analysis

KW - tyrosine kinase receptors

UR - http://www.scopus.com/inward/record.url?scp=2342437556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2342437556&partnerID=8YFLogxK

U2 - 10.1016/j.gassur.2004.01.006

DO - 10.1016/j.gassur.2004.01.006

M3 - Article

C2 - 15120370

AN - SCOPUS:2342437556

VL - 8

SP - 448

EP - 453

JO - Journal of Gastrointestinal Surgery

JF - Journal of Gastrointestinal Surgery

SN - 1091-255X

IS - 4

ER -